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Summary: To determine the feasibility and effectiveness of inte-
grating highly active antiretroviral therapy (HAART) into existing
tuberculosis directly observed therapy (TB/DOT) programs, we per-
formed a pilot study in an urban TB clinic in South Africa. Patients
with smear-positive pulmonary TB were offered HIV counseling and
testing. Twenty HIV-positive patients received once-daily didanosine
(400 mg) plus lamivudine (300 mg) plus efavirenz (600 mg) admin-
istered concomitantly with standard TB therapy Monday to Friday
and self-administered on weekends. After completing TB therapy,
patients were referred to an HIV clinic for continued treatment. At
baseline, patients had a mean CD4 count of 230 cells/mm3 (range:
24–499 cells/mm3) and a mean viral load of 5.75 log10 (range: 3.81–
7.53 log10). Seventeen completed combined standard TB and HIV
therapy; 16 of 20 (80%) patients enrolled and 15 of 17 (88%) patients
completing standard TB therapy achieved a viral load <50 copies/mL
and mean CD4 count increase of 148 cells/mm3. TB was cured in 17
of 20 (85%) enrolled patients and 17 of 19 (89%) patients with drug-
sensitive TB. Treatment was well tolerated, with minimal gastrointes-
tinal, hepatic, skin, or neurologic toxicity. The project was well ac-
cepted and integrated into the daily TB clinic functions. This pilot
study demonstrates that TB/DOT programs can be feasible and effec-
tive sites for HIV identification and the introduction and monitoring
of a once-daily HAART regimen in resource-limited settings.
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Tuberculosis (TB) is a major cause of morbidity and mor-tality among persons with HIV disease worldwide, par-
ticularly in resource-poor settings. The province of KwaZulu
Natal is the most populous of the 9 provinces in South Africa
and is most severely affected by the HIV pandemic.1,2 As in
many resource-limited settings, the HIV epidemic in KwaZulu
Natal is accompanied by a severe TB epidemic. Approxi-
mately two thirds of TB patients are coinfected with HIV,
which results in a high annual case fatality rate of approxi-
mately 40%.2
Highly active antiretroviral therapy (HAART) has dra-
matically altered the natural history of HIV disease in indus-
trialized countries.3 High cost, weak infrastructure, and lack of
political will have limited HAART availability in resource-
constrained settings such as KwaZulu Natal, however.4 The
existence of TB directly observed therapy (DOT) programs
and the recent availability of less costly, safer, and more con-
venient HAART regimens provide a unique but as yet untested
opportunity to integrate the treatment of TB and HIV disease.
This is particularly true because TB/DOT programs are de-
signed to enhance and support medication adherence, which is
crucial for therapeutic success for both diseases. Treating TB
and HIV disease concomitantly may potentially improve the
outcome for each. Challenges to implementing such a strategy
include (1) disruption and overburdening of TB health care
services, (2) excessive cost, (3) overlapping and additive drug
interactions and toxicities,5,6 (4) paradoxic and immune recon-
stitution syndromes,7 and (5) potential decreased program and
medication adherence.8 To begin to address these issues, we
conducted a pilot feasibility study integrating HAART into an
existing TB/DOT program in an urban metropolitan public TB
clinic, the Prince Cyril Zulu Communicable Diseases Clinic in
Durban, KwaZulu Natal, South Africa.
MATERIALS AND METHODS
Setting
The Prince Cyril Zulu Communicable Diseases Clinic is
a public municipal clinic providing TB diagnosis and treat-
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ment for the metropolitan area of Durban, KwaZulu Natal.
DOT is provided on-site or through referral to community care
settings once the diagnosis of TB is established.
Patients
Eligibility criteria included sputum smear–positive pul-
monary TB, confirmed HIV infection, 18 years of age or
greater, receipt of standard TB therapy, resident of the greater
Durban area, and ability to attend the TB/DOT program at the
Cyril Zulu Communicable Diseases Clinic daily. Pregnant and
breast-feeding women and those not able to practice reliable
contraception were excluded, as were patients with baseline
liver enzymes >5 times the upper limit of normal, a history of
pancreatitis, significant peripheral neuropathy, prior antiretro-
viral treatment, and a CD4 cell count >500 cells/mm3. Patients
provided written informed consent.
Study Procedures
HIV voluntary counseling and testing (Vironostika
HIV-1/HIV-2, Organon Teknika; Murex HIV 1+2 GAC, Mu-
rex Wellcozyme) were offered to consecutive patients with
sputum smear–positive pulmonary TB. Consecutive patients
found to be HIV-positive were offered study participation, and
after providing written informed consent, they were screened
for study eligibility. Those meeting eligibility requirements
were enrolled.
The study was designed to employ standard procedures,
practices, and definitions used by the clinic and recommended
by the South Africa National Tuberculosis Control Program.9
Patients received standard TB treatment as per the clinic pro-
tocol, consisting of an intensive phase of rifampicin, isoniazid,
pyrazinamide, and ethambutol in single-combination tablets
according to a subject’s weight for 2 months. TB drugs were
administered under direct observation from Monday to Friday.
After 2 months of the intensive phase of TB treatment, 2 drugs
(rifampicin and isoniazid) in single combination tablets were
administered in a continuation phase daily from Monday to
Friday for the remaining treatment period, which was usually
4 months. Management and assessment of the response to TB
treatment were carried out according to the South African Na-
tional Tuberculosis Control Program Guidelines.9 Patients
identified as HIV-positive but not meeting the study entry
criteria were offered referral to the HIV Clinic at the Nelson
R. Mandela School of Medicine for further assessment and
follow-up.
HAART was administered concomitantly with TB
medications. Patients received and ingested their TB and HIV
medications at the same time under direct observation by the
clinic staff nurses. This was routinely done in the morning at
about 9:00 AM. Two daily dose packs of HIV medication were
provided on Friday for weekend self-administration at home.
The regimen, consisting of once-daily administration of 400
mg of didanosine (ddI; in tablet formulation, dose adjusted to
300 mg if patient weight <60 kg), 300 mg of lamivudine (3TC),
and 600 mg of efavirenz, was chosen on the basis of drug avail-
ability in South Africa at the time of ethical approval and ex-
isting data about pharmacologic properties, clinical efficacy,
and potential interactions with TB medications.10–12
Assessments for evidence of drug toxicity and clinical
efficacy were initially done weekly for the first 4 weeks and
then monthly thereafter; they consisted of clinical evaluations
and laboratory tests with particular attention to gastrointesti-
nal, neurologic, dermatologic, and psychiatric adverse effects.
CD4 cell counts (FACScan; Becton Dickinson) and viral load
testing (Nuclisens HIV-1 QT) were done at baseline and every
2 months during concomitant treatment. HIV genotypic resis-
tance was determined at baseline and at 6 months by means of
plasma specimens obtained from patients with detectable virus
(ViroSeq; Applied Biosystems) and was compared with ref-
erence strains in the Stanford HIV Database (http://hivdb.
Stanford.Edu/hiv/).
Adverse events were assessed for severity using the
AIDS Clinical Trials Group (ACTG)/Community Program for
Clinical Research on AIDS (CPCRA) grading scheme
(http://www.nih.gov). Each Monday morning, a standardized
validated questionnaire adopted for local use was administered
by study staff regarding weekend medication adherence.8 So-
cial support was enhanced during the study and included on-
going counseling by clinic and research staff. Transportation
costs were provided as needed. No financial incentives were
provided.
Medical and nursing staff at the Cyril Zulu Clinic were
trained in the study procedures and provided and observed
medication administration as with other clinic patients. In ad-
dition, the research team consisted of a specialist physician on
a 20% basis and a nurse and administrative assistant on a 50%
basis each. On successful completion of anti-TB treatment, the
patients were transferred to the Infectious Disease Clinic of the
King Edward VIII Hospital, the teaching hospital of the Nel-
son R. Mandela School of Medicine, University of Kwa Zulu
Natal, for continued antiretroviral therapy.
All patient materials were available in English and Zulu.
Study data were collected on standardized case report forms.
Results were analyzed for all patients who took 1 or more
doses of HAART and for those completing the treatment
protocol.
The Ethics Committee of the Nelson R. Mandela School
of Medicine, University of Kwa Zulu Natal, and the Human
Investigations Committee, Yale University School of Medi-
cine, approved the study.
RESULTS
From January 2002 to June 2002, 92 consecutive pa-
tients with smear-positive pulmonary TB were counseled and
tested for HIV and offered study participation. Of these, 59
(64%) tested positive and 20 met entry criteria and were en-
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rolled in the study, of whom 15 were women and 5 were men,
with a mean age of 31 years (range: 18–53 years), a mean CD4
count of 230 cells/mm3 (range: 24–499 mm3), and a mean viral
load of 5.75 log10 (range: 3.81–7.53 log10). Of the remaining
39 patients who were not enrolled, 6 declined participation, 8
did not return for their results, 13 were referred to outlying
clinics for TB treatment, 7 were unable to attend clinic daily
for DOT, 3 had CD4 counts >500 cells/mm3, and 2 did not
meet the medical entry criteria.
Ten patients commenced HAART within 2 weeks of
starting TB medication: 8 between 1 and 2 months and 2 after
2 months. Seventeen of the 20 enrolled patients completed
standard TB therapy as defined by the South African National
Tuberculosis Control Program.9 Two patients withdrew dur-
ing the study, and 1 of these was lost to follow-up. One patient
was retrospectively diagnosed as having multidrug-resistant
TB at study enrollment and was hospitalized to receive second-
line TB therapy and continue antiretroviral therapy.
Eighteen of 20 patients (90%) reported an improvement
in physical and mental health. Sixteen of the 20 (80%) enrolled
patients achieved a viral load <50 copies/mL at 24 weeks
(Figs. 1, 2), and 15 of 17 (88%) patients who completed con-
comitant standard TB and HIV treatment achieved a viral load
<50 copies/mL (see Figs. 1, 2). Among those who completed
standard TB and HIV therapy, there was a mean increase of
148 CD4 cells/mm3 (range: 20–379 cells/mm3) (Fig. 3). Of the
2 patients on standard TB therapy and HAART who did not
achieve complete viral suppression, 1 was nonadherent to
HAART and the other was unexplained. Two patients without
baseline resistance mutations were documented to have devel-
oped resistance at 24 weeks to 3TC, ddI, and efavirenz. Both
patients developed V106M, Y181C, and G190S mutations. In
addition, 1 patient developed K65R, and the other patient de-
veloped L74V, K101E, M184V, and R219N mutations.
TB cure as defined by the South African Tuberculosis
Control Program9 was achieved over a period of 6 to 12
months in 17 of 20 (85%) enrolled patients and in 17 of 19
(89%) patients with drug-sensitive TB. Thirteen patients were
cured of TB after 6 months of therapy, 3 after 7 months, and 1
at 10 months.
HAART and TB medications were well tolerated. One
patient withdrew after 2 weeks of therapy because of medica-
tion adverse effects, including loss of appetite, vomiting, diar-
rhea, abdominal pain, difficulty in sleeping, nightmares, and
dizziness. In addition, social circumstances contributed to her
discontinuation of therapy, because she was unable to disclose
her HIV status to her employer and was therefore not able to
come to the clinic on a daily basis. The most common medi-
cation adverse effects reported were dizziness and poor con-
centration in 8 (40%) patients and insomnia in 2 (10%) pa-
tients. These symptoms presented in the first few weeks after
initiation of therapy and then subsided and were ascribed to
efavirenz. Two patients transiently took off from work during
this period as a result of these symptoms. Other reported symp-
toms were fatigue in 9 (45%) patients, vomiting in 3 (15%),
abdominal pain and rash in 3 (15%), and diarrhea in 2 (10%).
Apart from the patient noted previously, these symptoms were
of grade 1 and 2 in severity and did not warrant discontinuation
of HAART therapy.
FIGURE 1. Percent of all enrolled patients with non-detectable
viral load (<50 copies).
FIGURE 2. Twenty patients were enrolled: 19 remained on
study and 17 completed standard TB and antiretroviral
therapy and achieved a viral load <50 copies at 24 weeks.
†, withdrew at 2 weeks; *, unrecognized multidrug-resistant
TB on enrollment; #, poorly adherent, ¶, antiretroviral resis-
tance.
FIGURE 3. Change in mean CD4 cell count in patients on
standard TB and antiretroviral therapy.
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The patients adhered well to the study requirements,
missing only 5.5% of the 2078 weekday clinic visits and asso-
ciated HAART and TB medication doses. The median number
of missed visits was 1 per patient (range: 0–68 missed visits).
The number of physician clinical monitoring visits per patient
ranged between 9 and 14 over the entire study period. Among
those patients who continued in the study, only 2 missed phy-
sician appointments. One missed 2 appointments after sustain-
ing multiple fractures after a motor vehicle accident. A second
patient who relocated during the course of the study continued
taking TB medications but could not be located for approxi-
mately 3 months and was therefore not on HAART during this
period. Apart from these 2 patients, all patients received week-
end medication throughout the study and reported 100% week-
end adherence. The study was well accepted by clinic staff and
seemed to be well integrated into the clinic’s procedures and
practice.
At the time of study, the South African Rand (R) was
approximately 11.00 to the US dollar and 10.00 to the Euro.
The cost of treating pulmonary TB within the TB/DOT pro-
gram in the Cyril Zulu Communicable Diseases Clinic was
$345 per patient for 6 months, including personnel, medica-
tions, chest radiography, and laboratory tests. The cost of in-
corporating HAART into the TB/DOT program during this pe-
riod was $1286 per patient, assuming a TB treatment duration
of 6 months. Sixty percent of this cost, $777 per patient, was
related to the purchase of the antiretroviral drugs. Laboratory
monitoring contributed $272 per patient, and $237 per patient
was expended for additional study personnel costs.
DISCUSSION
This pilot study represents the first reported attempt to
integrate HAART into an existing TB/DOT program in a re-
source-poor setting. The results of the study are encouraging
and, although preliminary, support the feasibility and utility of
this strategy. The study provides additional preliminary evi-
dence regarding the efficacy and toxicity of a once-daily regi-
men of HAART in patients with HIV and TB.10–14
We have demonstrated that (1) it is feasible to introduce
HAART into an existing TB/DOT program in a metropolitan
clinic without disrupting or compromising clinic routines and
practice, (2) a once-daily HAART regimen of efavirenz, 3TC,
and ddI administered concomitantly with a standard rifampi-
cin-based TB treatment regimen during TB/DOT is effective
and well tolerated, (3) adherence to self-medication of
HAART over weekends is excellent, (4) a high TB cure rate
can be achieved, and (5) the additional cost of the strategy is
largely related to the cost of antiretroviral therapy.
Rabkin et al13 have succinctly outlined the challenges
and opportunities related to the provision of antiretroviral
treatment in resource-poor settings. Further, it has been argued
that structured implementation of HAART may prevent “anti-
retroviral anarchy” in sub-Saharan Africa.14 The high burden
of disease caused by HIV and TB coinfection in South Africa
and other resource-poor countries, the challenge of adherence
to medication,8 and the widespread existence of the TB/DOT
infrastructure recommend these programs as logical and ap-
pealing but previously untested sites for the structured intro-
duction of antiretroviral therapy. The results of this pilot study
suggest that introducing HAART through an existing TB/DOT
program is a structured implementation that can be feasible,
safe, effective, and acceptable to the patients and staff at these
facilities.
This study also adds to the literature on therapeutic in-
terventions that address the co-occurrence of HIV and TB.
Studies from Brazil and South Africa suggest that the use of
HAART in patients coinfected with HIV and TB but without
active disease lowers the subsequent incidence of active
TB.15,16 In most resource-poor settings, however, patients with
HIV disease come to clinical attention with already active TB.
In this pilot study, we have addressed this common scenario by
employing directly observed therapy with both TB and HIV
medications in an attempt to improve the outcome of the 2
diseases.
Directly observed therapy for TB was introduced more
than 40 years ago as a method of ensuring medication adher-
ence and treatment completion and decreasing the risk of drug-
resistant TB. This strategy has become a central component of
the Directly Observed Therapies (DOTS) strategy recom-
mended by the World Health Organization (WHO) for treat-
ment of TB.17 More recently, successful DOT programs were
noted to be those that supplemented observation of medication
taking with several other components, including enhanced
staff motivation and patient-centered supportive program ele-
ments.18 In the present study, medication administration under
observation and social support were features of the design and
likely contributed to its success.
Although the utility of administration of HAART by
DOT has been questioned,19 the availability of potent once-
daily regimens makes this strategy more practical, particularly
in the setting of an existing TB once-daily regimen. The avail-
ability of once-daily dosing of HAART has improved toler-
ability while maintaining efficacy and safety and is expected
to increase adherence, reduce drug resistance, and improve
clinical outcomes in the long term.20,21 Modified community-
based HAART through DOT support has been successful in
special settings in developed countries.22,23 Of relevance to the
present study, this strategy of DOT HAART has also been
successfully employed in a resource-poor setting in Haiti
among patients with advanced HIV disease, although without
active TB.24
This study employed a once-daily regimen of ddI, 3TC,
and efavirenz. This regimen was chosen based on medication
availability in South Africa, known compatibility with ri-
fampin, potency, and available literature on once-daily antiret-
roviral therapy regimens.10–12 This regimen has also been ad-
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ministered successfully during TB treatment in Brazil.25 This
study is the first report of the coadministration of this once-
daily regimen with TB medications through an existing
TB/DOT program, however.
Many physicians and experts currently recommend de-
lay of HAART initiation in patients presenting with TB be-
cause of added pill burden and concern about drug interac-
tions, toxicity, and risk of immune reconstitution events. In the
present study, the added number of pills did not seem to com-
promise adherence to HAART during either concomitant ad-
ministration with TB medication or weekend home self-
administration. Future once-daily regimens should result in a
further decrease in the required number of pills. Dean et al26
demonstrated the effectiveness of concomitant TB and
HAART treatment, although such therapy was associated with
significant adverse events leading to interruptions in TB/HIV
therapy. In our pilot study, medications were well tolerated,
with only 1 patient withdrawing because of a combination of
drug adverse effects and social issues. For 2 other patients,
treatment interruptions were the result of environmental and
social factors. Immune reconstitution events were not identi-
fied in this study, and the 1 patient who deteriorated clinically
was found to have multidrug-resistant TB.
Overall, in this pilot feasibility study, 17 of 19 (89%)
patients with drug-sensitive TB receiving standard therapy
were cured. The WHO has reported an average worldwide TB
treatment success rate of 82% for the year 2000 utilizing a
DOTS strategy. Treatment success was substantially below
average in the African region (72%), however.27 In South Af-
rica, these rates have been variable, ranging from 54% to 89%
in published studies.28,29 The TB cure rate in the province of
KwaZulu Natal in 1999 was 40%,30 and data for 2001 for the
clinic where this study was conducted showed a cure rate of
66.5% for new smear-positive TB (personal communication,
Dr. Surie Chinappa, 2003). Although the number of partici-
pants in the present pilot study was small and carefully se-
lected, the high TB cure rate suggests the possibility of another
potential benefit for treating both diseases together in this set-
ting.
HAART is considered a high-cost intervention in the
care of HIV disease in resource-constrained settings. Wilkin-
son et al31 estimated that it costs approximately $345 to cure a
patient with TB in South Africa. The major added cost associ-
ated with the addition of HAART to TB/DOT in this study was
that of antiretroviral medications. Thus, overall costs of the
strategy can be reduced substantially if costs of HAART can be
further reduced. Procurement and administration of less costly
HAART regimens in resource-limited settings remain major
challenges for this strategy and for the introduction of antiret-
roviral therapy in general. Laboratory monitoring added addi-
tional cost, but the frequency of CD4 cell counts and viral load
testing could be substantially reduced as is recommended for
clinical and public health practice.32
Although the results of this pilot study are encouraging,
several limitations should be recognized. The study included a
small number of patients and was carried out at a single site and
patients were ambulatory and selected to meet study entry cri-
teria, thereby potentially limiting the generalizability of the
findings. In addition, despite careful monitoring for adverse
effects and toxicities, the small size of the study may have lim-
ited the ability to detect important toxicities. Similarly, al-
though the study seemed to be accommodated well within
usual clinic activities, the small number of subjects, presence
of research staff, and absence of a formal analysis of clinic
functions limit this observation. Finally, the strategy failed in
2 patients who developed antiretroviral resistance. This may
be related to subtherapeutic drug levels resulting from de-
creased medication absorption or increased rifampicin-
induced metabolism of efavirenz. The correct dose of efavi-
renz for administration with rifampicin remains controversial.
Most recent recommendations favor maintaining the standard
600-mg dose,12 although others recommend increasing the
dose to 800 mg administered once daily.30 Other larger series
have successfully used the lower dose.25 The high frequency of
early efavirenz-induced adverse effects experienced by par-
ticipants in the present study suggests that using a higher dose
might be associated with an unacceptable adverse effect pro-
file and hazard to some patients. Further studies of the phar-
macokinetics of various doses of efavirenz in the presence of
rifampicin are needed to resolve this controversy.
We recognize that the coadministration of HAART and
TB therapy through the existing TB/DOT program does not
fully address the more long-term requirement for antiretroviral
therapy administration. This does not obviate the utility of the
strategy, however. We view this strategy as providing an entry
point for identification of eligible patients for HIV treatment
and initiation of HAART and the provision of an initial suc-
cessful structured experience with antiretrovirals, the benefits
of which may extend well into the subsequent period of long-
term self-administration.
The results of this pilot study warrant full and critical
evaluation in a large randomized trial of the short- and long-
term benefits and risks of concurrent versus deferred HAART
in coinfected patients treated within TB/DOT programs. Such
a trial is currently in development.33 In the meantime, given
the urgency of providing treatment of HIV disease in resource-
poor settings, the feasibility and utility of this strategy should
be confirmed at other sites and, if reproducible, should be
strongly considered for wider expansion.
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